Adaptive (ADPT) Q1 2026 Earnings Transcript

Adaptive Biotechnologies reported Q1 revenue of $70.9 million, up 45% year over year, with MRD revenue rising 53% to $67.1 million and sequencing gross margin expanding 800 bps to 70%. Management raised full-year MRD revenue guidance to $260 million-$270 million from $255 million-$265 million and now expects at least 35% clinical volume growth in 2026. The quarter also included the company’s first U.S. primary endpoint milestone, backlog growth to about $254 million, and continued progress in EMR integration, Medicaid coverage, and AI-driven immune medicine.

Analysis

The key market signal is not just top-line acceleration; it is that ADPT is converting adoption into operating leverage faster than the street likely modeled. The combination of rising blood-based mix, community penetration, and EMR integration creates a self-reinforcing workflow moat: once testing becomes embedded in standard order sets, volume should become less dependent on individual physician enthusiasm and more on protocolized behavior. That matters because it shifts the business from episodic “new product adoption” into a recurring utilization model, which supports a higher multiple than a typical diagnostics rollup.

The second-order effect is on pricing power and reimbursement durability. As the assay becomes the de facto standard in community networks, payer pushback gets harder because any utilization review starts to look like restricting care pathways rather than managing discretion. Texas Medicaid coverage is an early state-level proof point, but the real upside is that it can accelerate similar policy normalization in other states and commercial accounts, especially as EMR integrations reduce friction and make the test harder to omit. The hidden beneficiary here may be Pfizer: if ADPT’s autoimmune and oncology data assets prove useful, ADPT becomes a low-cost AI-enabled discovery partner with asymmetric optionality, even if that line item stays immaterial near term.

The contrarian risk is that consensus may be over-anchoring to a straight-line adoption curve while underestimating how lumpy pharma recognition can be and how quickly competition can force pricing concessions in narrower indications. The current guide lift looks conservative, but a lot of the near-term upside is already visible in volume; the stock will need either sustained sequential re-acceleration or proof that milestone-quality pharma revenue can recur, otherwise the multiple can stall even with strong fundamentals. This is a months-to-years story, not a days-only trade: the near-term catalyst stack is continued EMR rollout and payer wins, while the main reversal risk is a reimbursement scare or evidence that competitive intensity in DLBCL starts to compress ASP before volume fully scales.

Key Decisions for Investors

• Long ADPT common into the next 2-4 quarters: favorable risk/reward if the market is still valuing this as a subscale diagnostics story rather than a workflow-embedded platform; monitor for re-rating on evidence of sustained 30%+ volume growth and margin expansion.
• Buy ADPT Jan-2027 call spreads on pullbacks: use upside exposure to capture a multi-quarter multiple expansion if community adoption and EMR pull-through continue; cap premium risk because pharma revenue remains lumpy.
• Pair trade: long ADPT / short a broad diagnostics basket or lower-moat lab names over 6-12 months: ADPT has clearer operational leverage and reimbursement optionality, while peers face more commoditized pricing and less workflow lock-in.
• If holding PFE, consider ADPT as an indirect AI/autoimmune optionality beneficiary over 12-24 months: the partnership is not yet revenue-driving for PFE, but it adds discovery leverage with limited balance-sheet risk.
• Set a tactical risk trigger on ADPT if ASP trends flatten below the current mid-teens trajectory or if quarterly volume growth slips below 25%: that would signal the moat is intact but the re-rating thesis is stalling.